27777170|t|Rheumatoid arthritis, insulin resistance, and diabetes
27777170|a|Recent progress in the management of rheumatoid arthritis (RA) is turning attention toward comorbidities, such as diabetes. The objectives of this review are to clarify the links between RA and diabetes and to assess potential effects of disease-modifying antirheumatic drugs (DMARDs) on diabetes. The increased insulin resistance seen in RA is closely linked to the systemic inflammation induced by certain proinflammatory cytokines such as tumor necrosis factor α (TNFα) and interleukin-6. The prevalence of type 2 diabetes is increased in patients with RA. Furthermore, certain DMARDs including hydroxychloroquine, methotrexate, TNFα antagonist, and interleukin-1β antagonists seem to improve the markers of glucose metabolism. In contrast, glucocorticoids tend to adversely affect glycemic control, particularly when taken chronically. Consequently, a crucial yet insufficiently applied rule is that cardiovascular risk factors must be sought and treated routinely, particularly as the choice of the DMARD may affect glucose metabolism.
27777170	0	20	Rheumatoid arthritis	T047	C0003873
27777170	22	40	insulin resistance	T046	C0021655
27777170	46	54	diabetes	T047	C0011847
27777170	78	88	management	T058	C0376636
27777170	92	112	rheumatoid arthritis	T047	C0003873
27777170	114	116	RA	T047	C0003873
27777170	146	159	comorbidities	T078	C0009488
27777170	169	177	diabetes	T047	C0011847
27777170	202	208	review	T170	C0282443
27777170	242	244	RA	T047	C0003873
27777170	249	257	diabetes	T047	C0011847
27777170	265	271	assess	T058	C0184514
27777170	272	289	potential effects	T080	C1280500
27777170	293	330	disease-modifying antirheumatic drugs	T121	C0242708
27777170	332	338	DMARDs	T121	C0242708
27777170	343	351	diabetes	T047	C0011847
27777170	357	366	increased	T081	C0205217
27777170	367	385	insulin resistance	T046	C0021655
27777170	394	396	RA	T047	C0003873
27777170	422	443	systemic inflammation	T047	C3646020
27777170	463	488	proinflammatory cytokines	T116,T129	C0079189
27777170	497	520	tumor necrosis factor α	T116,T129	C1456820
27777170	522	526	TNFα	T116,T129	C1456820
27777170	532	545	interleukin-6	T116,T129	C0021760
27777170	565	580	type 2 diabetes	T047	C0011860
27777170	584	593	increased	T081	C0205217
27777170	597	605	patients	T101	C0030705
27777170	611	613	RA	T047	C0003873
27777170	636	642	DMARDs	T121	C0242708
27777170	653	671	hydroxychloroquine	T109,T121	C0020336
27777170	673	685	methotrexate	T109,T121	C0025677
27777170	687	691	TNFα	T116,T129	C1456820
27777170	692	702	antagonist	T120	C0243076
27777170	708	722	interleukin-1β	T116,T129	C0021753
27777170	723	734	antagonists	T120	C0243076
27777170	743	750	improve	T033	C0184511
27777170	755	762	markers	T123	C1513159
27777170	766	784	glucose metabolism	T044	C0596620
27777170	799	814	glucocorticoids	T109,T125	C0017710
27777170	840	856	glycemic control	T061	C3267174
27777170	959	986	cardiovascular risk factors	T047	C0850624
27777170	1006	1023	treated routinely	T169	C1522326
27777170	1059	1064	DMARD	T121	C0242708
27777170	1076	1094	glucose metabolism	T044	C0596620